![Paul Clancy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Clancy
Presidente presso
SIONNA THERAPEUTICS, INC.
Patrimonio netto: 3 M $ in data 30/09/2026
Profilo
Paul J.
Clancy is currently Independent Non-Executive Chairman at Sionna Therapeutics, Inc. since 2022, Independent Director at Incyte Corp.
since 2015, and Secretary, Director & Vice President at Stromedix, Inc. Former roles include Chairman at Xilio Therapeutics, Inc. from 2022 to 2026, President & Director at Bioverativ Therapeutics, Inc., Independent Director at Agios Pharmaceuticals, Inc. from 2013 to 2023, Independent Director at EXACT Sciences Corp.
from 2021 to 2026, Chief Financial Officer & Executive VP-Finance at Biogen, Inc. from 2007 to 2017, Chief Financial Officer & Executive Vice President at Biogen Idec New Ventures, Inc., Senior Vice President-Finance at Biogen Idec, Inc. (North Carolina), Executive Vice President at Alexion Pharmaceuticals, Inc. from 2019 to 2020, and VP & General Manager-Great West Business Unit at PepsiCo, Inc. from 1997 to 2000.
Education includes undergraduate studies at Babson College and an MBA from Columbia Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
INCYTE CORPORATION 0,01% | 30/09/2026 | 25.838 ( 0,01% ) | 3 M $ | 30/09/2026 |
| 17/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
Posizioni attive di Paul Clancy
| Società | Posizione | Inizio |
|---|---|---|
| INCYTE CORPORATION | Direttore/Membro del Consiglio | 20/01/2015 |
| SIONNA THERAPEUTICS, INC. | Presidente | 06/06/2022 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Paul Clancy
| Società | Posizione | Fine |
|---|---|---|
| EXACT SCIENCES CORPORATION | Direttore/Membro del Consiglio | 23/03/2026 |
| XILIO THERAPEUTICS, INC. | Presidente | 06/01/2026 |
| AGIOS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 13/06/2023 |
| ALEXION PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/11/2019 |
| BIOGEN INC. | Direttore Finanziario/CFO | 13/06/2017 |
Formazione di Paul Clancy
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
85
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
PepsiCo, Inc.
 PepsiCo, Inc. Food: Specialty/CandyConsumer Non-Durables Makes, markets, distributes and sells beverages & convenient food products | Consumer Non-Durables |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
EXACT Sciences Corp.
 EXACT Sciences Corp. Medical SpecialtiesHealth Technology Develops proprietary technologies for the detection of cancer | Health Technology |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Babson College
 Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
